Enigma Diagnostics receives patent for amplification consumables

Enigma Diagnostics Limited, the decentralised and point-of-care molecular diagnostics company, announced today that the U.S. Patent and Trademark Office has granted U.S. Patent No. 7,659,096 with claims that cover the use of amplification consumables in several current real-time and end point PCR instruments. The consumables incorporate a thermally conducting layer and reaction wells in combination with a reaction mixture and a blocking agent. Enigma Diagnostics Ltd is the exclusive licensee of this patent from the UK Defence Science Technology Laboratory.

This is the most recent patent to issue in Enigma's expanding portfolio of over 300 patents and patent applications. This portfolio includes patents relating to intelligent sample preparation consumables and novel amplification technologies for current and 'next generation' molecular diagnostic systems and sample preparation devices. Enigma continues to expand its worldwide licensing programme and awareness of its broadly applicable and important IP portfolio which now includes this US patent.